Hybridoma Cell Line B6GE1, Monoclonal Antibody to the Specific Peptide-MHC Class II Complex

Hybridoma Cell Line B6GE1 as described in Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13856-61 and developed in the laboratory of Dr. Ronald Germain.

Potential Commercial Applications: Competitive Advantages:
  • A research material that can be used in the development of assays, validation of products or in quality control.
  • Speed up product development with NIH developed material that has already been tested and validated.


Ronald Germain (NIAID)  ➽ more inventions...

Intellectual Property:
Research Material – Patent protection is not being pursued for this technology. (IC Reference No. 1999-006)

Zhong G, et al. PMID 9391117

Licensing Contact:
Charles Rainwater,
Email: crainwater@niaid.nih.gov
Phone: 301-496-2644

OTT Reference No: B-020-1999/0
Updated: Dec 4, 2017